Liminal B subtypes of breast cancer are positive in the expression of ER, PR, and HER2 receptors (ER+/PR+/HER2+) and the expression of markers like CK7, CK8, CK18, and CK19 and show an up-regulation of genes related to cell proliferation [4, 5]. Here, ERBB2 is linked to breast carcinoma.